STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2797 by analyst upside · 2026-08-12
ACAD
ACADIA Pharmaceuticals Inc.
Healthcare · Market Cap $5B · P/E 13.2x
ANALYST PRICE TARGET
+13.9%
implied upside to consensus target
Current Price $29.41
Consensus Target $33.5
Bull Target $45.0
Bear Target $17.0
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
11
Hold
4
Sell
1
52-Week Low $19.69
52-Week High $29.76
YTD Return +11.9%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) 13.2x
Forward P/E 32.8x
EPS (TTM) $2.23
PEG Ratio 50.86
Dividend Yield N/A
Revenue (TTM) $1.1B
Profit Margin 33.4%
52-WEEK RANGE
52-Week Low $19.69
52-Week High $29.76
Current Price $29.41
Bear Target $17.0
Bull Target $45.0
● Now $29.41 ● Target $33.5
TRADING DATA
Avg Volume 1.6M
YTD Return +11.9%
Analyst Count 20
Consensus Buy
Upside to Target +13.9%
Last Updated 2026-08-12

ANALYST SUMMARY

ACADIA Pharmaceuticals Inc. (ACAD) is currently trading at $29.41 with a Wall Street consensus price target of $33.5, implying potential upside of 13.9% over the next 12 months. 20 analysts currently cover ACAD, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $17.0.

ACAD operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 11.9% year-to-date and is currently trading near the upper end of its 52-week range of $19.69 – $29.76.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ACAD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-05-08 Building track record
B of A Securities ↑ Upgrade
Neutral → Buy 2026-03-25 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-04 43% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-02-26 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-02-26 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-02-26 Building track record
Stifel - Reiterated
Hold → Hold 2026-02-26 Building track record
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
23/30
Consensus clarity
11/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →